

MAXIM.073DV1C1.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : K. Gehlsen ) Group Art Unit: Unknown  
App. No. : Unknown )  
Filed : Herewith )  
For : METHODS AND )  
COMPOSITIONS FOR TOPICAL )  
TREATMENT OF DAMAGED )  
TISSUE USING REACTIVE )  
OXYGEN METABOLITE )  
PRODUCTION OR RELEASE )  
INHIBITORS )  
Examiner : Unknown )

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
PO Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that were previously disclosed and/or cited by the Applicant in the prosecution in related applications hereto, U.S. Application No. 09/765,929, filed on January 19, 2001, which is a divisional of U.S. Application No. 09/227,801, filed on January 8, 1999, now U.S. Patent No. 6,270,781. The present application claims the priority date of the parent of this continuation application under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).



**Appl. No.** : Unknown  
**Filed** : Herewith

This Information Disclosure Statement is being filed within three months of the filing date of this application, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6 P5B9002

By: 

James J. Mullen III, Ph.D.

Registration No. 44,957

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

S:\DOCS\MKD\MKD-2481.DOC\020602

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.073DV1C1	APPLICATION NO. Unknown
	APPLICANT Gehlsen, K.R.	
	FILING DATE Herewith	GROUP Unknown

 1c971 U.S. PTO  
 10/068447

02/06/02

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		4,307,076	12/22/81	Harvey et al.			
		4,573,996	03/04/86	Kwiatek et al.			
		4,597,961	07/01/86	Etscom			
		4,839,174	06/13/89	Baker et al.			
		4,857,328	08/15/89	Trenzeluk			
		4,908,213	03/13/90	Govil et al.			
		4,943,435	06/24/90	Baker et al.			
		5,166,620	05/26/92	Chvapil et al.			
		5,122,127	06/16/92	Stanley			
		5,160,731	11/03/92	Sabatelli et al.			
		5,288,497	02/22/94	Stanley et al.			
		5,294,440	03/15/94	Jack et al.			
		5,328,454	07/12/94	Sibalis			
		5,336,168	08/09/94	Sibalis			
		5,474,527	12/12/95	Bettinger			
		5,558,914	12/24/96	Cohen et al.			
		5,676,969	10/14/97	Wick et al.			
		5,679,337	10/21/97	Jack et al.			
		5,716,610	02/10/98	Jack et al.			
		5,804,203	09/08/98	Hahn et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		93/21904	11/11/93	WO				
		✓ 95/23601	09/08/95	WO				
		✓ 97/42968	11/20/97	WO				
		97/42968	11/20/97	WO				

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.073DV1	APPLICATION NO. Unknown
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Gehlsen, K.R.	
		FILING DATE Herewith	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	A	Babior, et al., THE JOURNAL OF CLINICAL INVESTIGATION, 52(3): 714-744 (1973)
		"Biological Defense Mechanisms: The production by leukocytes of superoxide, a potential bacterial agent".
	B	Imamura, et al., PATHOLOGY INTERNATIONAL, 47(1): 16-24 (1997), "Involvement of tumor necrosis factor- $\gamma$ , interleukin-1 $\beta$ ,
		interleukin-8, and interleukin-1 receptor antagonist in acute lung injury caused by local Schwartzman reaction".
	C	Paul and Sbarra, BIOCHIMA ET BIOPHYSICA ACTA, 156: 168-178 (1968)
		"The Role of the Phagocyte in Host-Parasite Interactions".
	D	Martindale - The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.),
		Remington's Pharmaceutical Sciences.
	E	CFTA Cosmetic Ingredient Handbook, 2 <sup>nd</sup> Edition, eds. John A. Wenninger and G.N. McEwen, Jr. (CTFA, 1992).
	F	Anthony, L.L. (ed.), "A Formulary of Cosmetic Preparations (Vol. Two) - Creams, Lotions and Milks," Micelle Press (England, N.J., 1993).
	G	<a href="http://www.shaperite.com/prod/pc24.html">http://www.shaperite.com/prod/pc24.html</a> , "Smooth-Rite Pain Cream" (10/16/98)
	H	<a href="http://www.cyberspike.com/chiro/remedies/hist15.html">http://www.cyberspike.com/chiro/remedies/hist15.html</a> , "Histamine", BioPharma - All Natural Homeopathic Remedies (12/21/98)
	I	21 CFR Ch. 1 §310.545 (4-1-98 Edition)
	J	Brune, M. et al. (1996) NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur.J.Haematol. 57:312-319.

EXAMINER	DATE CONSIDERED
<b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

S:\DOCS\MKD\MKD-2482.DOC  
020602